The Winship Cancer Institute (Winship) at Emory University is a university-based cancer center that supports, facilitates and coordinates all cancer research, cancer care and cancer-related education within Emory University, Winship is the first and only NCI-designated cancer center in the state of Georgia, the 8th most populous state in the union. As such, Winship is a transformative leader in integrating cancer research and care aimed at reducing the burden of cancer for the citizens of Georgia and the Southeastern region. Winship has a strong commitment to the inclusion of minorities in clinical research, with approximately 30% of participants in its clinical research trials in 2012 identified as African- American. Winship investigators are conducting innovative therapeutic and non-therapeutic trials across the oncology spectrum. The accomplishments presented in this application are highly relevant to Winship's participation in NCI National Clinical Trials Network (NCTN) and to the growing collaborative research opportunities available between the NCI NCTN network groups and Winship. Winship has participated in clinical trials conducted by all ten of the currently existing NCI-supported cancer cooperative groups. Over the past 5 years Winship investigators have accrued over 500 adult patients to cooperative group clinical trials at Emory University and its affiliates. We have seen a steady increase in accruals over this time period demonstrated by a greater than 50% increase in accruals between 2007 and 2012. This demonstrates the commitment of Winship to continue to provide benefit to our patients through innovative clinical research. Winship investigators have also led the accrual of over 488 young adult and adolescent patients to COG trials since 2007. During the same time period, Winship investigators have designed and/or chaired over 20 trials through the adult cooperative groups. The goal of this application is to sustain and increase the level of engagement between Winship and the NCTN and its network groups in terms of scientific and administrative leadership as well as accrual to NCTN trials.

Public Health Relevance

Winship investigators have played a major role in the national cooperative groups by providing leadership to various disease committees and groups. They have also been consistent contributors to patient accrual as evidenced by a steady Increase in number of patients accrued to cooperative group studies at Winship. Combined with our scientific strengths, patient resources, especially accrual of minority patients, Winship is wel positioned to make robust contributions to the NCTN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180864-04
Application #
9236164
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-05-06
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
4
Fiscal Year
2017
Total Cost
$542,798
Indirect Cost
$194,905
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Childress, Merrida A; Himmelberg, Stephen M; Chen, Huiqin et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res 16:1724-1736
Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Almodovar, Karinna; Iams, Wade T; Meador, Catherine B et al. (2018) Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. J Thorac Oncol 13:112-123
Rakovitch, E; Gray, R; Baehner, F L et al. (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169:359-369
Du, Zhenfang; Lovly, Christine M (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17:58
Pillai, Rathi N; Behera, Madhusmita; Owonikoko, Taofeek K et al. (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer 124:271-277
Belinsky, Steven A; Leng, Shuguang; Wu, Guodong et al. (2017) Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence. Cancer Prev Res (Phila) 10:635-640
Leng, Shuguang; Wu, Guodong; Klinge, Donna M et al. (2017) Gene methylation biomarkers in sputum as a classifier for lung cancer risk. Oncotarget 8:63978-63985
Wakelee, Heather A; Dahlberg, Suzanne E; Keller, Steven M et al. (2017) Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 18:1610-1623

Showing the most recent 10 out of 67 publications